BioNTech SE on X: “📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall…”

A fast, private reader for public X posts. No account, no tracking, no pop-ups.

PeekX is an independent tool and is not affiliated with, endorsed by or sponsored by X Corp. “X” and “Twitter” are trademarks of their respective owners. We only show posts that their authors made public and never access private or protected accounts. Downloaded media belongs to its creators — please respect their rights.

BioNTech SE on X: “📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall…” | PeekX

Username or post link

Home / @BioNTech_Group / Post

BioNTech SE

@BioNTech_Group

📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall survival data from the PRESERVE-003 Phase 3 trial for a chemotherapy-free CTLA-4-targeting immunotherapy in 2L+ squamous non-small cell lung cancer.
🔗 Learn more: bit.ly/4h5DjqL
#LungCancer #WCLC26

Sep 14, 2026, 2:17 PM UTC

1 31

Download media

Every quality X serves, straight from X's media CDN. No watermark, no wait.

OriginalBEST

#1 · Photo · 3276×4096

OriginalBEST

#2 · Photo · 3277×4096

Save & share

Turn this post into a clean image, or copy it as text or Markdown.

Open on X